Prime Medicine, Inc. 8K

Prime Medicine reported Q2 2026 results and major pipeline milestones, including global trial clearance for PM577a, arbitration success securing PM647 rights, RMAT designation for PM359, and cash runway into 2027.

On August 6, 2026, Prime Medicine, Inc. reported its financial results for the quarter ended June 30, 2026 and provided business updates, highlighting regulatory clearances for its PM577a Wilson disease program in the United States and New Zealand to support a global Phase 1/2 trial with initial data expected in 2027, a favorable binding arbitration outcome with Beam Therapeutics that affirms Prime Medicine’s rights to the PM647 Alpha-1 Antitrypsin Deficiency program with anticipated IND/CTA submission in the third quarter of 2026, and U.S. FDA Regenerative Medicine Advanced Therapy designation for PM359 for chronic granulomatous disease as the company engages with the FDA toward a planned BLA submission in the first half of 2027, while noting second quarter R&D and G&A expense reductions, a net loss of $42.1 million, and a cash position of $108.8 million expected to fund operations into 2027.

Filing Facts

CIK

1894562

Ticker

PRME

Form

8K

Source Type

fda

Accession

0001628280-26-053878

Alert Tier

7